🚀 VC round data is live in beta, check it out!
Integral Diagnostics Valuation Multiples
Discover revenue and EBITDA valuation multiples for Integral Diagnostics and similar public comparables like Lumibird, Innovita Biological Tech, RaySearch Labs, Garofalo Health Care and more.
Integral Diagnostics Overview
About Integral Diagnostics
Integral Diagnostics is a major Australian diagnostic imaging provider. In Australia, imaging revenues are almost entirely earned via the public health Medicare system. Integral typically earns approximately 90% of group revenue from diagnostic imaging in Australia and the remainder from diagnostic imaging in Auckland, New Zealand. In Australia, Integral services regional areas in Queensland, Victoria, New South Wales, and Western Australia.
Founded
2008
HQ
Employees
3.0K
Website
Financials (LTM)
EV
$1B
Integral Diagnostics Financials
Integral Diagnostics reported last 12-month revenue of $514M and EBITDA of $104M.
In the same LTM period, Integral Diagnostics generated $498M in gross profit, $104M in EBITDA, and $30M in net income.
Revenue (LTM)
Integral Diagnostics P&L
In the most recent fiscal year, Integral Diagnostics reported revenue of $441M and EBITDA of $78M.
Integral Diagnostics expects next 12-month revenue of XXX and NTM EBITDA of XXX
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Revenue | $514M | XXX | $441M | XXX | XXX | XXX |
| Gross Profit | $498M | XXX | $422M | XXX | XXX | XXX |
| Gross Margin | 97% | XXX | 96% | XXX | XXX | XXX |
| EBITDA | $104M | XXX | $78M | XXX | XXX | XXX |
| EBITDA Margin | 20% | XXX | 18% | XXX | XXX | XXX |
| EBIT Margin | 11% | XXX | 10% | XXX | XXX | XXX |
| Net Profit | $30M | XXX | $21M | XXX | XXX | XXX |
| Net Margin | 6% | XXX | 5% | XXX | XXX | XXX |
| Net Debt | — | — | $203M | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
Integral Diagnostics Stock Performance
Integral Diagnostics has current market cap of $640M, and enterprise value of $1B.
Market Cap Evolution
Integral Diagnostics' stock price is $1.72.
| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $1B | $640M | 0.0% | XXX | XXX | XXX | $0.06 |
Benchmark Trading Valuation Multiples by Industry
Sign up to access valuation multiples like growth-adjusted P/E, Rule of 40, next 12-month EV/Revenue, EBITDA multiples by industry, consensus analyst estimates and many more.
Start Free TrialIntegral Diagnostics Valuation Multiples
Integral Diagnostics trades at 2.0x EV/Revenue multiple, and 10.0x EV/EBITDA.
EV / Revenue (LTM)
Integral Diagnostics Financial Valuation Multiples
As of March 9, 2026, Integral Diagnostics has market cap of $640M and EV of $1B.
Equity research analysts estimate Integral Diagnostics' 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Integral Diagnostics has a P/E ratio of 21.3x.
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $640M | XXX | $640M | XXX | XXX | XXX |
| EV (current) | $1B | XXX | $1B | XXX | XXX | XXX |
| EV/Revenue | 2.0x | XXX | 2.4x | XXX | XXX | XXX |
| EV/EBITDA | 10.0x | XXX | 13.3x | XXX | XXX | XXX |
| EV/EBIT | 17.7x | XXX | 24.8x | XXX | XXX | XXX |
| EV/Gross Profit | 2.1x | XXX | 2.5x | XXX | XXX | XXX |
| P/E | 21.3x | XXX | 31.2x | XXX | XXX | XXX |
| EV/FCF | 41.5x | XXX | 100.6x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Verified Integral Diagnostics Valuation Multiples
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2027, based on consensus analyst estimates. Powered by FactSet and Morningstar.
Integral Diagnostics Margins & Growth Rates
Integral Diagnostics' revenue in the last 12 month grew by 14%.
Integral Diagnostics' revenue per employee in the last FY averaged $0.2M.
Integral Diagnostics' rule of 40 is 34% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
Integral Diagnostics' rule of X is 56% (created by Bessemer, rule of X is another metric to measure SaaS companies, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
Integral Diagnostics Operational Valuation Multiples
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Revenue Growth | 14% | XXX | 27% | XXX | XXX | XXX |
| EBITDA Margin | 20% | XXX | 18% | XXX | XXX | XXX |
| EBITDA Growth | 19% | XXX | 49% | XXX | XXX | XXX |
| Rule of 40 | — | XXX | 34% | XXX | XXX | XXX |
| Bessemer Rule of X | — | XXX | 56% | XXX | XXX | XXX |
| Revenue per Employee | — | XXX | $0.2M | XXX | XXX | XXX |
| G&A Expenses to Revenue | 2% | XXX | 67% | XXX | XXX | XXX |
| Opex to Revenue | — | XXX | 86% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Integral Diagnostics Public Comps
See public comps and valuation multiples for other Hospitals & Clinics and Laboratory Services comps.
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| LTM | 2026E | 2027E | LTM | 2026E | 2027E | |
| Lumibird | XXX | XXX | XXX | XXX | XXX | XXX |
| Innovita Biological Tech | XXX | XXX | XXX | XXX | XXX | XXX |
| RaySearch Labs | XXX | XXX | XXX | XXX | XXX | XXX |
| Garofalo Health Care | XXX | XXX | XXX | XXX | XXX | XXX |
| OncoclĂnicas | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Integral Diagnostics M&A Activity
Integral Diagnostics acquired XXX companies to date.
Last acquisition by Integral Diagnostics was on XXXXXXXX, XXXXX. Integral Diagnostics acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Acquisitions by Integral Diagnostics
| Acquired Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Get Verified M&A Valuation Multiples
Sign up to see revenue and EBITDA valuation multiples for 150K+ M&A deals.
Start Free TrialIntegral Diagnostics Investment Activity
Integral Diagnostics invested in XXX companies to date.
Integral Diagnostics made its latest investment on XXXXXXXX, XXXXX. Integral Diagnostics invested in XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Investments by Integral Diagnostics
| Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples
Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.
Start Free TrialAbout Integral Diagnostics
| When was Integral Diagnostics founded? | Integral Diagnostics was founded in 2008. |
| Where is Integral Diagnostics headquartered? | Integral Diagnostics is headquartered in Australia. |
| How many employees does Integral Diagnostics have? | As of today, Integral Diagnostics has over 3K employees. |
| Who is the CEO of Integral Diagnostics? | Integral Diagnostics' CEO is Ian Kadish. |
| Is Integral Diagnostics publicly listed? | Yes, Integral Diagnostics is a public company listed on Australian Securities Exchange. |
| What is the stock symbol of Integral Diagnostics? | Integral Diagnostics trades under IDX ticker. |
| When did Integral Diagnostics go public? | Integral Diagnostics went public in 2015. |
| Who are competitors of Integral Diagnostics? | Integral Diagnostics main competitors are Lumibird, Innovita Biological Tech, RaySearch Labs, Garofalo Health Care. |
| What is the current market cap of Integral Diagnostics? | Integral Diagnostics' current market cap is $640M. |
| What is the current revenue of Integral Diagnostics? | Integral Diagnostics' last 12 months revenue is $514M. |
| What is the current revenue growth of Integral Diagnostics? | Integral Diagnostics revenue growth (NTM/LTM) is 14%. |
| What is the current EV/Revenue multiple of Integral Diagnostics? | Current revenue multiple of Integral Diagnostics is 2.0x. |
| Is Integral Diagnostics profitable? | Yes, Integral Diagnostics is EBITDA-positive (as of the last 12 months). |
| What is the current EBITDA of Integral Diagnostics? | Integral Diagnostics' last 12 months EBITDA is $104M. |
| What is Integral Diagnostics' EBITDA margin? | Integral Diagnostics' last 12 months EBITDA margin is 20%. |
| What is the current EV/EBITDA multiple of Integral Diagnostics? | Current EBITDA multiple of Integral Diagnostics is 10.0x. |
| What is the current FCF of Integral Diagnostics? | Integral Diagnostics' last 12 months FCF is $25M. |
| What is Integral Diagnostics' FCF margin? | Integral Diagnostics' last 12 months FCF margin is 5%. |
| What is the current EV/FCF multiple of Integral Diagnostics? | Current FCF multiple of Integral Diagnostics is 41.5x. |
Start Your
Free Trial Today
Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.